Remepy (remepy.com), a New York-based company developing Hybrid Drugs that pair traditional pharmaceuticals with AI-driven digital protocols into a single regulated prescription, has raised $36 million in Series A funding led by O.G. Venture Partners and M Ventures. The approach combines the biological mechanism of a drug with personalized digital interventions measured and adapted by AI. The capital will advance Phase III trials of Hybridopa for Parkinson's disease and expand pharmaceutical partnerships.
PDURS Pathway Enables Drug-Software Combinations
The timing comes amid growing interest in drug-digital combinations: Click Therapeutics raised $50M Series D from Boehringer Ingelheim in 2026, while Akili Interactive has raised over $160M. Remepy's approach — owning the full drug pipeline end-to-end — addresses the reimbursement challenges that led to Pear Therapeutics' bankruptcy.
Phase IIa Data Shows Doubled Drug Effect
Parkinson's patients treated with Hybridopa showed a 9.7-point improvement on the MDS-UPDRS scale versus 1.95 for placebo in a double-blind Phase IIa trial, with 90% achieving clinically meaningful response. Current levodopa treatments see motor fluctuations in over 50% of patients within five years. Standalone digital therapeutics have struggled with reimbursement, as seen with Pear Therapeutics' 2023 bankruptcy.
Hybrid Model Integrates Drug and App
Remepy pairs Levodopa with DopApp, an AI-driven protocol targeting motor, cognitive, speech, and mental function. Unlike Click Therapeutics' licensing model or Akili's standalone games, Remepy owns the drug end-to-end and pursues FDA's PDURS framework for inclusion on drug labels. This creates a new category of Hybrid Drugs regulated and reimbursed like pharmaceuticals.
"The app essentially added as much benefit as the molecule itself." — Dr. Michal Tsur
Strategic Investors Signal Pharma Validation
M Ventures, Merck KGaA's corporate venture arm, led the round alongside O.G. Venture Partners. The investment follows Remepy's April 2026 collaboration with Merck KGaA on rare tumors and other areas, validating the hybrid approach with a top-10 pharma partner.
Digital Therapeutics Market Expands Rapidly
The digital therapeutics market is projected to grow from $10.9B–$12.6B in 2026 to $35.4B–$93.4B by 2031, with prescription DTx specifically moving from $5.6B in 2024 to $24.9B by 2032. Key drivers include the FDA's 2023 PDURS guidance and pharma's need for differentiation amid patent expirations.
Serial Founders Bring Biotech Credibility
Co-CEOs Dr. Michal Tsur, who previously co-founded Kenshoo (acquired by Skai), and Or Shoval lead the company. Scientific advisor Prof. Michal Schwartz from the Weizmann Institute brings pioneering neuroimmunology expertise.
Phase III Trial and Pipeline Expansion Ahead
With deployments advancing, Remepy plans to initiate Hybridopa Phase III in Q4 2026 and pursue additional pharma partnerships in oncology and women's health.